• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers
Mycosis fungoides (MF) and Sézary syndrome (SS) comprise approximately 53% of cutaneous lymphomas. Both MF and SS may clinically and histologically mimic benign skin conditions, posing a diagnostic challenge to the dermatologist. Precise clinicopathologic correlation is necessary to support a diagnosis, especially in the early stages of disease. In addition to the identification of histopathologic criteria, ancillary studies, including the identification of CD4+ T cells with aberrant immunophenotypes and T-cell receptor gene rearrangements within skin lesions and peripheral blood are used to support the diagnosis. Recent ...
Source: Journal of the American Academy of Dermatology - January 16, 2014 Category: Dermatology Authors: Sarah I. Jawed, Patricia L. Myskowski, Steven Horwitz, Alison Moskowitz, Christiane Querfeld Tags: Continuing Medical Education Source Type: research

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) Part II. Prognosis, management, and future directions
Both mycosis fungoides (MF) and Sézary syndrome (SS) have a chronic, relapsing course, with patients frequently undergoing multiple, consecutive therapies. Treatment is aimed at the clearance of skin disease, the minimization of recurrence, the prevention of disease progression, and the preservation of quality of life. Other important considerations are symptom severity, including pruritus and patient age/comorbidities. In general, for limited patch and plaque disease, patients have excellent prognosis on ≥1 topical formulations, including topical corticosteroids and nitrogen mustard, with widespread patch/plaque diseas...
Source: Journal of the American Academy of Dermatology - January 16, 2014 Category: Dermatology Authors: Sarah I. Jawed, Patricia L. Myskowski, Steven Horwitz, Alison Moskowitz, Christiane Querfeld Tags: Continuing Medical Education Source Type: research

Hodgkin lymphoma: 2014 update on diagnosis, risk‐stratification, and management
Disease overview: Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 9,200 new patients annually and representing approximately 11.5% of all lymphomas in the United States. Diagnosis: HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte‐predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups under the designation of classical HL. Risk stratification: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therap...
Source: American Journal of Hematology - June 20, 2014 Category: Hematology Authors: Stephen M. Ansell Tags: A Continuing Medical Education Series Source Type: research

Cutaneous T‐cell lymphoma: 2014 Update on diagnosis, risk‐stratification, and management
Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data. Risk‐adapted therapy: TNMB (tumor, node, metastasis, and blood) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed ...
Source: American Journal of Hematology - July 14, 2014 Category: Hematology Authors: Ryan A. Wilcox Tags: A Continuing Medical Education Series Source Type: research

Multiple malignancies after Hodgkin lymphoma
Source: Blood - July 17, 2014 Category: Hematology Tags: CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

How I treat HIV-Hodgkin lymphoma
Source: Blood - February 19, 2015 Category: Hematology Tags: CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

Exam 1: Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis
Source: Clinical Gastroenterology and Hepatology - March 16, 2015 Category: Gastroenterology Tags: Continuing Medical Education (CME) Activities Source Type: research

The aggressive peripheral T‐cell lymphomas: 2015
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - May 30, 2015 Category: Hematology Authors: James O. Armitage Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Mantle Cell Lymphoma: 2015 Update on Diagnosis, Risk‐Stratification and Clinical Management
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - June 23, 2015 Category: Hematology Authors: Julie M. Vose Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Waldenstr öm macroglobulinemia: 2017 update on diagnosis, risk stratification, and management
Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients. Risk Stratification: Age, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis. Risk‐Adapt...
Source: American Journal of Hematology - January 16, 2017 Category: Hematology Authors: Morie A. Gertz Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Risk of heart failure following Hodgkin lymphoma
Source: Blood - April 20, 2017 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

The aggressive peripheral T ‐cell lymphomas: 2017
Source: American Journal of Hematology - May 18, 2017 Category: Hematology Authors: James O. Armitage Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Mantle cell lymphoma: 2017 update on diagnosis, risk ‐stratification, and clinical management
Abstract Disease OverviewMantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4‐5 years. DiagnosisDiagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki�...
Source: American Journal of Hematology - July 12, 2017 Category: Hematology Authors: Julie M. Vose Tags: ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Source Type: research

Predicting transformation of follicular lymphoma
Source: Blood - July 20, 2017 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20